RecruitingNCT07312526
Shanghai Clinical Cohort - Esophageal Cancer
Shanghai Clinical Cohort - Esophageal Cancer Cohort
Sponsor
Shanghai Chest Hospital
Enrollment
2,116 participants
Start Date
Jul 1, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
A prospective cohort of patients who received esophagectomy for esophageal cancer in participating centers.
Eligibility
Inclusion Criteria1
- Received esophagectomy in these centers for esophageal cancer.
Exclusion Criteria1
- No esophagectomy.
Interventions
PROCEDUREesophagectomy
esophagectomy
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07312526
Related Trials
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
NCT051871821 location
Resilience and Equity in Aging, Cancer, and Health (REACH)
NCT046742671 location
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
NCT0646994443 locations
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
NCT0721770410 locations
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT0644597243 locations